Stahl Stephen M, Laredo Sarah, Morrissette Debbi Ann
Neuroscience Education Institute, Carlsbad, CA, USA.
Arbor Scientia, Carlsbad, CA, USA.
Ther Adv Psychopharmacol. 2020 Feb 12;10:2045125320905752. doi: 10.1177/2045125320905752. eCollection 2020.
Cariprazine is one of the newest dopamine-serotonin partial agonists, also known as 'atypical' second generation antipsychotics. Originally approved for acute and maintenance treatment of schizophrenia as well as for acute mania and mixed mania/depression, cariprazine has now been approved for bipolar I depression. Additionally, analyses of bipolar I depressed subjects show that both those with and those without concurrent manic features were improved following treatment with cariprazine. Maintenance studies are in progress in bipolar disorder, as are studies to augment antidepressants in unipolar major depressive episodes insufficiently responsive to treatment. Here, we review specifically the efficacy and safety data of cariprazine in bipolar I disorder and discuss the hypothesized mechanism of action of cariprazine and how it could theoretically be linked to caprazine's broad therapeutic actions across the mood disorder spectrum.
卡立普嗪是最新的多巴胺 - 5-羟色胺部分激动剂之一，也被称为“非典型”第二代抗精神病药物。卡立普嗪最初被批准用于精神分裂症的急性和维持治疗以及急性躁狂症和混合性躁狂/抑郁症，目前已被批准用于治疗双相I型抑郁症。此外，对双相I型抑郁症患者的分析表明，无论有无并发躁狂特征的患者，在接受卡立普嗪治疗后病情均有改善。双相情感障碍的维持治疗研究正在进行中，同时也在进行关于增强对治疗反应不足的单相重度抑郁发作中抗抑郁药疗效的研究。在此，我们特别回顾卡立普嗪在双相I型障碍中的疗效和安全性数据，并讨论卡立普嗪的假定作用机制，以及从理论上它如何与卡立普嗪在整个心境障碍谱系中的广泛治疗作用相关联。
